PF-622 is primarily utilized in the field of medicinal chemistry and drug development. It functions as a selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), which plays a crucial role in the regulation of endocannabinoid signaling. By inhibiting FAAH, PF-622 increases the levels of endogenous cannabinoids, such as anandamide, in the body. This mechanism has potential therapeutic applications in the treatment of various neurological and psychiatric disorders, including anxiety, depression, and chronic pain. Additionally, its ability to modulate the endocannabinoid system makes it a candidate for research in inflammation and neurodegenerative diseases. PF-622 is also used in preclinical studies to better understand the physiological and pathological roles of the endocannabinoid system, aiding in the development of novel therapeutic agents.